Montelukast Sodium
FDA-approved product (tablet, oral), marketed as Montelukast Sodium, Singulair.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Rhinitis, Allergic, Perennial
- Seasonal allergic rhinitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Leukotriene receptor antagonists
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Montelukast Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection55.9% AI-predicted activityagainst E. coli50+ registered studies
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more55.8% AI-predicted activityagainst E. coli50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia55.8% AI-predicted activityagainst E. coli50+ registered studies
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation55.7% AI-predicted activityagainst E. coli50+ registered studies
- Setmelanotide AcetateExisting use: Obesity55.6% AI-predicted activityagainst E. coliNo documented evidence found
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more55.6% AI-predicted activityagainst E. coli50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma55.4% AI-predicted activityagainst E. coli50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted55.4% AI-predicted activityagainst E. coli50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema55.2% AI-predicted activityagainst E. coli33 registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder55.2% AI-predicted activityagainst E. coli21 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more55.2% AI-predicted activityagainst E. coli50+ registered studies
- LypressinExisting use: Vasopressin and analogues55.1% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
NCT00960141 · start 2000-08
Registered record
- Registry ID
- NCT00960141
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- montelukast sodium; Comparator: loratadine; Comparator: placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-08
- Completion
- 2000-11
- Enrolment
- 829
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionmontelukast sodium; Comparator: loratadine; Comparator: placeboPhasePhase 3Registry statusCompletedA Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease
NCT00162864 · start 1999-12
Registered record
- Registry ID
- NCT00162864
- Conditions
- Asthma; COPD
- Interventions
- montelukast sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-12
- Completion
- 2002-04
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthma; COPDInterventionmontelukast sodiumPhasePhase 3Registry statusCompletedChronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
NCT00968201 · start 1997-12
Registered record
- Registry ID
- NCT00968201
- Conditions
- Asthma
- Interventions
- montelukast sodium; Comparator: Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-12
- Completion
- 2001-03
- Enrolment
- 689
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionmontelukast sodium; Comparator: PlaceboPhasePhase 3Registry statusCompletedBioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted Conditions
NCT01928056
Registered record
- Registry ID
- NCT01928056
- Conditions
- Healthy
- Interventions
- Torrent's Montelukast Sodium Tablets 10 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTorrent's Montelukast Sodium Tablets 10 mgPhasePhase 1Registry statusCompletedBioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fed Conditions
NCT01928069
Registered record
- Registry ID
- NCT01928069
- Conditions
- Healthy
- Interventions
- Torrent's Montelukast Sodium Tablets 10 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTorrent's Montelukast Sodium Tablets 10 mgPhasePhase 1Registry statusCompleted